Technical Analysis for ALXO - ALX Oncology Holdings Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
180 Bullish Setup | Bullish Swing Setup | 4.65% | |
Wide Bands | Range Expansion | 4.65% | |
Upper Bollinger Band Walk | Strength | 13.98% | |
Wide Bands | Range Expansion | 13.98% | |
Overbought Stochastic | Strength | 13.98% | |
Down 3 Days in a Row | Weakness | 13.98% | |
New Uptrend | Bullish | 3.97% | |
Calm After Storm | Range Contraction | 3.97% | |
NR7 | Range Contraction | 3.97% |
Alert | Time |
---|---|
Up 3% | about 18 hours ago |
60 Minute Opening Range Breakout | about 18 hours ago |
Possible NR7 | about 18 hours ago |
Bullish 180 Entry | about 22 hours ago |
Rose Above Previous Day's High | about 22 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Oncology Cancer Immunotherapy Acute Myeloid Leukemia Epidermal Growth Factor Receptor Carcinoma Myelodysplastic Syndrome Syndromes Treatment Of Myelodysplastic Syndrome
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Oncology Cancer Immunotherapy Acute Myeloid Leukemia Epidermal Growth Factor Receptor Carcinoma Myelodysplastic Syndrome Syndromes Treatment Of Myelodysplastic Syndrome
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 17.42 |
52 Week Low | 3.9357 |
Average Volume | 510,625 |
200-Day Moving Average | 10.01 |
50-Day Moving Average | 13.66 |
20-Day Moving Average | 13.11 |
10-Day Moving Average | 14.72 |
Average True Range | 1.17 |
RSI (14) | 64.54 |
ADX | 26.2 |
+DI | 32.48 |
-DI | 16.93 |
Chandelier Exit (Long, 3 ATRs) | 13.52 |
Chandelier Exit (Short, 3 ATRs) | 14.01 |
Upper Bollinger Bands | 16.85 |
Lower Bollinger Band | 9.38 |
Percent B (%b) | 0.92 |
BandWidth | 56.94 |
MACD Line | 0.79 |
MACD Signal Line | 0.37 |
MACD Histogram | 0.4204 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 17.74 | ||||
Resistance 3 (R3) | 17.58 | 16.91 | 17.48 | ||
Resistance 2 (R2) | 16.91 | 16.53 | 16.99 | 17.40 | |
Resistance 1 (R1) | 16.57 | 16.29 | 16.74 | 16.73 | 17.31 |
Pivot Point | 15.90 | 15.90 | 15.99 | 15.98 | 15.90 |
Support 1 (S1) | 15.56 | 15.52 | 15.73 | 15.72 | 15.13 |
Support 2 (S2) | 14.89 | 15.28 | 14.97 | 15.04 | |
Support 3 (S3) | 14.55 | 14.89 | 14.96 | ||
Support 4 (S4) | 14.71 |